For laboratory research use only. Not for human consumption. Not for clinical or therapeutic use. Not evaluated by the FDA.
For laboratory research use only. Not for human consumption. Not for clinical or therapeutic use. Not evaluated by the FDA.
Before You Checkout
Bundle complementary compounds together — priced below buying each separately.
A synthetic analog of growth hormone-releasing hormone (GHRH) with Drug Affinity Complex (DAC). Researched in preclinical settings for its sustained receptor activation properties and extended signaling profile in growth hormone axis studies.
Dosage
5mg
Form
Lyophilized Powder
Bundle & Save
$49.95
Quantity
Research Application Guidelines
This research compound is designed exclusively for controlled in vitro studies carried out by trained professionals. It is not intended for human or animal use and must not be incorporated into foods, cosmetics, medications, or diagnostic processes.
Regulatory Notice
This material has not been evaluated by the FDA and is not sold for the purpose of diagnosing, treating, curing, or preventing any condition. All handling, storage, and research use must comply with applicable regulations and institutional requirements.
Purchase & Responsibility Agreement
By purchasing from Ascension Labs, the buyer confirms that they are a qualified researcher or authorized laboratory. All sales are final. The buyer assumes full responsibility for the proper handling, storage, usage, and regulatory compliance of this material.
What's Included
Storage Guidelines
Quality Assurance
Disclaimer: Our peptides are research-grade products for laboratory use only. They are not approved for human consumption or medical use. Always follow proper laboratory safety protocols.
CJC-1295 is a synthetic growth-hormone-releasing-hormone (GHRH) analog with Drug Affinity Complex (DAC) for an extended half-life. It is studied in vitro for sustained GHRH-receptor activation in growth-hormone-axis research.
Also referred to as: CJC1295, CJC-1295 DAC, GHRH analog, DAC:GRF.
CJC-1295 is a synthetic growth-hormone-releasing-hormone (GHRH) analog studied as an agonist at the GHRH receptor. Its Drug Affinity Complex (DAC) binds circulating albumin, extending activity duration in research models. In growth-hormone-axis studies, sustained receptor activation and downstream cAMP signaling are characterized in vitro to understand prolonged GHRH-receptor stimulation.
CJC-1295 is a modified fragment of GHRH(1-29) carrying amino-acid substitutions that resist enzymatic breakdown, plus a Drug Affinity Complex (a maleimido group) that covalently binds albumin. This lipid-free, albumin-tethering design places it in the long-acting GHRH-analog class. It is characterized structurally by these stabilizing modifications rather than by an exact molecular weight.
The two share the same modified GHRH(1-29) backbone, but the DAC variant adds an albumin-binding complex that markedly extends its half-life in research models. Without DAC (modified GRF 1-29), the peptide acts over a much shorter window. Comparative studies use this difference to examine sustained versus pulsatile GHRH-receptor activation.
Yes. Every batch of CJC-1295 W/ DAC is independently tested by HPLC and mass spectrometry, and ships with a lot-specific Certificate of Analysis verifying 99.3% purity and molecular identity.
Store lyophilized CJC-1295 W/ DAC at -20°C for long-term storage or 2-8°C short-term. After reconstitution, keep refrigerated at 2-8°C and avoid repeated freeze-thaw cycles.
No. CJC-1295 W/ DAC is sold strictly for in-vitro research and laboratory use only. It is not a drug or supplement and is not intended for human or animal consumption.